CASSAVA SCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
FLNA$0.49+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share data)
| Years ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating expenses: | |||
| Research and development, net of grant reimbursement | $89,423 | $68,032 | $24,813 |
| General and administrative | 16,534 | 11,988 | 8,055 |
| Total operating expenses | 105,957 | 80,020 | 32,868 |
| Operating loss | (105,957) | (80,020) | (32,868) |
| Interest income | 7,833 | 2,777 | 49 |
| Other income, net | 907 | 997 | 434 |
| Net loss | $(97,217) | $(76,246) | $(32,385) |
| Net loss per share, basic and diluted | $(2.32) | $(1.90) | $(0.82) |
| Shares used in computing net loss per share, basic and diluted | 41,932 | 40,202 | 39,405 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.